Breast Lesion Guidance Systems Market Revenue, Opportunity, Forecast and Value Chain 2016-2024

Global Breast Lesion Guidance Systems Market: Overview 

According to the World Cancer Research Fund International, breast cancer is the most common cancer in women, with an estimated 1.7 million new cases diagnosed in 2012. The highest incidence of breast cancer was in North America and Oceania. The incidence of breast cancer in North America was estimated at 80 per 100,000 individuals in Canada and around 92 per 100,000 in the U.S.

Get a Copy of Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12656

This alarming rise in the incidence of breast cancer has resulted in an increasing awareness about the disease among women and a rise in the number of screening and imaging techniques in the market. Early detection of the malignancy of palpable and non-palpable breast lesions can result in effective and timely treatment of various breast abnormalities. This is one of the major factors driving the global breast lesion guidance systems market.

The report on the breast lesion guidance systems market evaluates the overall performance of the global market and determines its various driving forces. The key challenges that lie ahead and recommendations by industry experts have also been included to give clients a well-rounded assessment of the breast lesion guidance systems market.

Global Breast Lesion Guidance Systems Market: Trends and Opportunities 

The increasing acknowledgment of the limitations of conventional localization methods identified by surgeons has increased the demand for alternative techniques of breast lesion localization. Technical challenges pertaining to excision and same-day wire placement have led to the development of advanced breast lesion guidance systems. The favorable reimbursement scenario for breast cancer treatment in several developed countries, the increase in the number of breast cancer surgeries, and the promising ongoing research in the field have also contributed to the growth of the breast lesion guidance systems market.

However, regulatory approval procedures are immensely lengthy and complex due to the risks associated with several breast lesion localization devices. This is likely to hamper the growth of the global market. Success in eliminating these risks and producing safer localization devices is thus a major opportunity for players operating in the global breast lesion guidance systems market.

Global Breast Lesion Guidance Systems Market: Treatment Outlook 

The most widely used breast lesion guidance systems include wire-guided localization (WGL), magnetic tracers, electromagnetic reflectors, and radioisotope localization methods such as radio-guided occult lesion localization (ROLL) and radioactive seed localization (RSL). WGL involves the insertion of a wire to the center of the lesion. The ROLL method is a new technique for the localization and removal of non-palpable lesions. It involves intratumoral insertion of a radioactive tracer. In the RSL technique, an iodine seed is implanted in the center of the tumor.

There have been several studies and trials comparing and reviewing the effectiveness of various breast lesion guidance systems. Cochrane, an England-based non-profit, non-governmental firm dedicated to medical research and reviews, conducted a major study in March 2015. The organization studied the performance of wire-guided localization, the most widely used and conventional approach for the surgical removal of non-palpable breast lesions, against modern alternatives such as ROLL and RSL.

The study found that people who opted for ROLL and WGL treatment presented similar results with regard to localization and removal of the lump. The post-operative complication rates of both methods were also similar. However, compared to WGL, ROLL treatment had lower re-intervention rates and resulted in slightly fewer positive tumor margins. In terms of successful location of the lesion, WGL was found to be superior to RSL. However, in terms of the successful removal of the lump, both techniques were found to be equally effective. Compared to WGL, RSL resulted in fewer positive tumor margins.

The results of the Cochrane study revealed that WGL continues to be a safe and tested breast lesion localization method, considering the statistical insignificance of the increase in effectiveness brought about by new alternatives. At the same time, RSL and ROLL have also been shown to be equally reliable and can be offered as a comparable alternative for WGL, should WGL be difficult to perform on a patient.

Request TOC of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12656

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com

This release was published on openPR.